SG46238A1 - New use of omega-3-fatty acids - Google Patents

New use of omega-3-fatty acids

Info

Publication number
SG46238A1
SG46238A1 SG1996001422A SG1996001422A SG46238A1 SG 46238 A1 SG46238 A1 SG 46238A1 SG 1996001422 A SG1996001422 A SG 1996001422A SG 1996001422 A SG1996001422 A SG 1996001422A SG 46238 A1 SG46238 A1 SG 46238A1
Authority
SG
Singapore
Prior art keywords
omega
pct
preparations
fatty acids
dic
Prior art date
Application number
SG1996001422A
Other languages
English (en)
Inventor
Nils Egberg
Carin Larsson-Backstrom
Jan Jakobsson
Rolf Lundh
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of SG46238A1 publication Critical patent/SG46238A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG1996001422A 1992-02-24 1993-02-23 New use of omega-3-fatty acids SG46238A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9200541A SE9200541D0 (sv) 1992-02-24 1992-02-24 New usee of omega-3-fatty acids

Publications (1)

Publication Number Publication Date
SG46238A1 true SG46238A1 (en) 1998-02-20

Family

ID=20385410

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996001422A SG46238A1 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids

Country Status (13)

Country Link
US (2) US5747533A (fr)
EP (1) EP0627918B1 (fr)
JP (1) JP3559280B2 (fr)
AT (1) ATE207744T1 (fr)
AU (1) AU671438B2 (fr)
CA (1) CA2117535A1 (fr)
DE (1) DE69331051T2 (fr)
DK (1) DK0627918T3 (fr)
ES (1) ES2162620T3 (fr)
NO (1) NO309704B1 (fr)
SE (1) SE9200541D0 (fr)
SG (1) SG46238A1 (fr)
WO (1) WO1993016691A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
US6313167B1 (en) * 1997-06-16 2001-11-06 Nippon Suisan Kaisha Ltd. Composition having capability of removing risk factor during exercise
CA2227706C (fr) * 1998-01-21 2010-08-03 Patrick Pageat Pheromones d'apaisement pour diminuer le stress, l'anxiete et l'agressivite de porcs
US6054481A (en) 1998-01-21 2000-04-25 Fideline Pig appeasing pheromones for enhancing weight gain in a mammal
BR9917806B1 (pt) * 1998-01-21 2013-06-18 composiÇço de feromona para tratamento de estresse ou ansiedade em mamÍferos, e soluÇço.
WO2001037827A1 (fr) * 1999-10-13 2001-05-31 Chacon Marco A Intervention therapeutique visant a reproduire l'effet d'une restriction calorique
FR2804023B1 (fr) * 2000-01-26 2002-09-20 Johnson & Johnson Consumer Fr Complement nutritionnel a base d'huile de pepins de cassis
JP2004527501A (ja) * 2001-03-05 2004-09-09 ピー． アーネスト，スティーヴン 経腸処方
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
WO2006036967A1 (fr) 2004-09-28 2006-04-06 Atrium Medical Corporation Solubilisation d'un medicament utilise dans un revetement
WO2007011385A2 (fr) 2004-09-28 2007-01-25 Atrium Medical Corporation Gel thermodurcissable et son procede de fabrication
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
EP2083875B1 (fr) 2006-11-06 2013-03-27 Atrium Medical Corporation Filet chirurgical enrobe
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080207756A1 (en) * 2007-02-27 2008-08-28 Atrium Medical Corporation Bio-absorbable oil suspension
WO2009009040A2 (fr) * 2007-07-06 2009-01-15 Baum Seth J Compositions d'acide gras et procédés d'utilisation
CA2702577A1 (fr) 2007-10-15 2009-04-23 Jbs United, Inc. Procede permettant d'accroitre la performance d'une progeniture
EP2211881A4 (fr) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine Compositions et procédés de prévention et de traitement de maladies touchant des mammifères
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100323028A1 (en) * 2007-11-30 2010-12-23 Jbs United, Inc. Method and composition for treating pulmonary hemorrhage
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
WO2011103514A1 (fr) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Émulsions de triglycéride dha
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
EP2593141B1 (fr) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition et procédés destinés à modifier la vitesse d'hydrolyse de substances vulcanisées à base d'huile
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US10183044B2 (en) * 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US9655847B1 (en) * 2016-07-18 2017-05-23 National Guard Health Affairs Therapeutic liposome and method of treating a subject having cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3785667T2 (de) * 1986-09-17 1994-07-21 Clintec Nutrition Co Zusatznahrung bzw. therapie für personen mit risiko oder in behandlung für arteriosklerotische vaskuläre, kardiovaskuläre und/oder thrombotische erkrankungen.
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8729751D0 (en) * 1987-12-21 1988-02-03 Norsk Hydro As Feed additive & feed containing such additive
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients

Also Published As

Publication number Publication date
ES2162620T3 (es) 2002-01-01
WO1993016691A1 (fr) 1993-09-02
DE69331051T2 (de) 2002-06-13
DE69331051D1 (de) 2001-12-06
NO943102D0 (no) 1994-08-23
JP3559280B2 (ja) 2004-08-25
NO943102L (no) 1994-10-21
EP0627918B1 (fr) 2001-10-31
ATE207744T1 (de) 2001-11-15
AU671438B2 (en) 1996-08-29
SE9200541D0 (sv) 1992-02-24
US5731346A (en) 1998-03-24
EP0627918A1 (fr) 1994-12-14
NO309704B1 (no) 2001-03-19
US5747533A (en) 1998-05-05
CA2117535A1 (fr) 1993-09-02
JPH07507766A (ja) 1995-08-31
DK0627918T3 (da) 2002-01-14
AU3652993A (en) 1993-09-13

Similar Documents

Publication Publication Date Title
SG46238A1 (en) New use of omega-3-fatty acids
Stephen et al. Scurvy identified in the emergency department: a case report
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
ZA200202990B (en) Water and oil containing emulsion.
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
PH25313A (en) Carboxylic acid derivatives, pharmaceutical compositions containing them
MD306C2 (ro) Remediu pentru profilaxia afecţiunilor vasculare, determinate de acţiunea peroxizilor glicoproteinfixaţi
Brown et al. Dietary protein intake and the glomerular adaptations to partial nephrectomy in dogs
Roba et al. Antiplatelet and antithrombogenic effects of suloctidil
BR9612346A (pt) Caseìna beta ou fragmentos de peptìdeo, produtos farmacêuticos e dietéticos derivados do leite ou o próprio leite, leite isento e contendo caseìna beta, processo de extração de caseìna beta do leite, processo para obter um produto dietético, uso de caseìna beta ou fragmentos de peptìdeo, uso de um produto farmacêutico ou alimentìcio dietético, e uso de leite para a prevenção de diabetes.
DE3584131D1 (de) Methode zur behandlung der antidiurese.
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
Chui et al. Cholesterol-rich LDL perfused at physiological LDL-cholesterol concentration induces platelet aggregation and PAF-acetylhydrolase activation
FR2603587A1 (fr) Derives de la 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonine (ou -1,4-benzoxazonine), procede pour leur preparation, medicaments les contenant et composes intermediaires
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
NO975155L (no) Anvendelse av forskolin eller ekstakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet
JPS57209218A (en) Antithrombotic
Paul et al. DISCUSSION ON DR. DAWBER'S PAPER (The Interrelationship of Tobacco Smoke Components to Hyperlipidemia and Other Risk Factors)
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
James Federal AIDS policy issues today
Al Aboud Medical Eponyms linked to nails
KR940011003A (ko) 우르솔린산을 함유하는 혈관형성 억제제 조성물
DE69629487D1 (de) Phosphoryliertes rekombinantes menschliches beta-kasein für die hemmung der anheftung von h. influenzae an menschlichen zellen
ATE99692T1 (de) Optisch aktive rhodiumkomplexe von 3,4bis(diarylphosphino)-pyrrolidinen und ihre verwendung zur herstellung von phosphinothricin durch asymmetrische hydrierung.